Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
doi:10.1378/chest.07-0299
(Chest. 2007; 132:1652-1658)
© 2007 American College of Chest Physicians
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hyzy, R.
Right arrow Articles by Martinez, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hyzy, R.
Right arrow Articles by Martinez, F.

Acute Exacerbation of Idiopathic Pulmonary Fibrosis*

Robert Hyzy, MD, FCCP; Steven Huang, MD; Jeffrey Myers, MD; Kevin Flaherty, MD, FCCP and Fernando Martinez, MD, FCCP

* From the Division of Pulmonary Medicine, University of Michigan Medical Center, Ann Arbor, MI.

Correspondence to: Robert C. Hyzy, MD, FCCP, Associate Professor of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109; e-mail: rhyzy{at}umich.edu

Abstract

Background: The clinical course of patients with idiopathic pulmonary fibrosis (IPF) is generally marked by a decline in pulmonary function over time. Increasingly, patients have been recognized as having an acute, and often fatal, clinical deterioration, termed an acute exacerbation of IPF (AE-IPF).

Methods: Review of the current literature pertaining to AE-IPF.

Results: Acute exacerbations are defined by an acute onset of dyspnea (< 1 month) with worsening hypoxia and progressive infiltrates seen in the absence of heart failure or infection. New ground-glass infiltrates are seen on chest CT scans with diffuse alveolar damage superimposed on a background of usual interstitial pneumonia that is evident on histopathology. The incidence is unknown and is impeded by difficulties in eliminating infection as a cause, as well as by reporting biases contained in reported series introduced by including only biopsied patients or only deaths, or by excluding patients with advanced disease. Prognosis is poor but may be influenced by diagnostic inaccuracy. Treatment with antiinflammatory therapies, such as corticosteroids, or with anticoagulation are unproven and have not as yet been fully studied.

Conclusions: AE of IPF is a complication that demands additional careful study to clarify its relationship to the clinical course of patients with IPF.

Key Words: chest CT scan • interstitial lung disease • lung biopsy • pathology lung • pulmonary fibrosis






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Chest Physicians.